Delek US CEO sells 80,000 shares in 10b5-1 plan

Q: What insider transaction did Delek US (DK) report for CEO Avigal Soreq on August 17, 2026?

Delek US reported that CEO Avigal Soreq sold 80,000 shares of common stock on 2026-08-17 in four open-market transactions under a Rule 10b5-1 trading plan, with each sale executed at a disclosed weighted average price.

Q: At what prices did the Delek US (DK) CEO sell shares in the latest Form 4?

The reported weighted average sale prices were $64.383, $65.351, $66.616, and $67.202 per share. Each figure reflects a weighted average sale price over multiple trades within specified intraday price ranges disclosed in the footnotes.

Q: How many Delek US (DK) shares did the CEO sell in each reported trade?

Avigal Soreq sold 4,603 shares at a $64.383 weighted average price, 4,623 shares at $65.351, 57,700 shares at $66.616, and 13,074 shares at $67.202, all classified as open-market or private sales of common stock.

Q: Does the latest Delek US (DK) Form 4 disclose the CEO’s holdings after the August 17, 2026 sales?

The Form 4 reports the 80,000 shares sold and related prices but does not provide a populated figure for total shares following the transactions, so post-transaction holdings are not detailed in this data set.

Delek US Holdings, Inc. (DK) reported that President & CEO Avigal Soreq sold a total of 80,000 shares of common stock on 2026-08-17 in four open‑market transactions under a Rule 10b5-1 trading plan.

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Delek US Holdings, Inc. (DK) reported that President & CEO Avigal Soreq sold a total of 80,000 shares of common stock on 2026-08-17 in four open‑market transactions under a Rule 10b5-1 trading plan. The weighted average sale prices were $64.383 for 4,603 shares, $65.351 for 4,623 shares, $66.616 for 57,700 shares, and $67.202 for 13,074 shares, with each price representing a weighted average over multiple trades within the disclosed intraday price ranges. A footnote states these trades were made pursuant to a 10b5‑1 plan intended to satisfy the affirmative defense conditions of Rule 10b5‑1(c) and that these transactions complete this plan.

Insights

Analyzing...

Insider Trade Summary 10b5-1

Net Seller: 80,000 shares

Net Sell 4 txns

Insider Soreq Avigal

Role President & CEO

Sold 80,000 shs ($5.32M)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2}	4,603	$64.383	$296K
Sale	Common Stock ^{F1, F3}	4,623	$65.351	$302K
Sale	Common Stock ^{F1, F4}	57,700	$66.616	$3.84M
Sale	Common Stock ^{F1, F5}	13,074	$67.202	$879K

Holdings After Transaction: Common Stock — 231,486 shares (Direct)

Footnotes (5)

F1. This transaction was made pursuant to a 10b5-1 plan and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). These transactions complete this plan.
F2. This price reflects the weighted average sale price of multiple transactions ranging from a low sale price of $63.985 per share to a high sale price of $64.950 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each sale price.
F3. This price reflects the weighted average sale price of multiple transactions ranging from a low sale price of $65.010 per share to a high sale price of $65.990 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each sale price.
F4. This price reflects the weighted average sale price of multiple transactions ranging from a low sale price of $66.135 per share to a high sale price of $67.130 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each sale price.
F5. This price reflects the weighted average sale price of multiple transactions ranging from a low sale price of $67.135 per share to a high sale price of $67.340 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each sale price.

Key Figures

Total shares sold: 80,000 shares Block sale 1: 4,603 shares at $64.383 per share Block sale 2: 4,623 shares at $65.351 per share +4 more

7 metrics

Total shares sold 80,000 shares Aggregate common stock shares sold by Avigal Soreq on 2026-08-17

Block sale 1 4,603 shares at $64.383 per share Open-market sale of common stock on 2026-08-17 (weighted average price)

Block sale 2 4,623 shares at $65.351 per share Open-market sale of common stock on 2026-08-17 (weighted average price)

Block sale 3 57,700 shares at $66.616 per share Open-market sale of common stock on 2026-08-17 (weighted average price)

Block sale 4 13,074 shares at $67.202 per share Open-market sale of common stock on 2026-08-17 (weighted average price)

Price range block 1 $63.985–$64.950 per share Intraday price range underlying the $64.383 weighted average sale price

Price range block 3 $66.135–$67.130 per share Intraday price range underlying the $66.616 weighted average sale price

Key Terms

Rule 10b5-1 plan, affirmative defense conditions of Rule 10b5-1(c), weighted average sale price, open market or private transaction

4 terms

Rule 10b5-1 plan regulatory

"This transaction was made pursuant to a 10b5-1 plan and is intended"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

affirmative defense conditions of Rule 10b5-1(c) regulatory

"intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)"

weighted average sale price financial

"This price reflects the weighted average sale price of multiple transactions"

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Delek US (DK) report for CEO Avigal Soreq on August 17, 2026?

Delek US reported that CEO Avigal Soreq sold 80,000 shares of common stock on 2026-08-17 in four open-market transactions under a Rule 10b5-1 trading plan, with each sale executed at a disclosed weighted average price.

At what prices did the Delek US (DK) CEO sell shares in the latest Form 4?

The reported weighted average sale prices were $64.383, $65.351, $66.616, and $67.202 per share. Each figure reflects a weighted average sale price over multiple trades within specified intraday price ranges disclosed in the footnotes.

Was the August 17, 2026 Delek US (DK) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 plan, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), and notes that these transactions complete the plan.

How many Delek US (DK) shares did the CEO sell in each reported trade?

Avigal Soreq sold 4,603 shares at a $64.383 weighted average price, 4,623 shares at $65.351, 57,700 shares at $66.616, and 13,074 shares at $67.202, all classified as open-market or private sales of common stock.

Do the Form 4 footnotes for Delek US (DK) provide price ranges for the CEO’s August 17, 2026 sales?

Yes. Each weighted average price is based on multiple trades within ranges: from $63.985–$64.950, $65.010–$65.990, $66.135–$67.130, and $67.135–$67.340 per share, with the CEO agreeing to provide detailed breakdowns upon written request.

Does the latest Delek US (DK) Form 4 disclose the CEO’s holdings after the August 17, 2026 sales?

The Form 4 reports the 80,000 shares sold and related prices but does not provide a populated figure for total shares following the transactions, so post-transaction holdings are not detailed in this data set.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/18/2026 - 08:12 PM EDT Accepted by SEC EDGAR 08/18/2026 - 08:12 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Soreq Avigal

(Last)

(First)

(Middle)

310 SEVEN SPRINGS WAY

SUITE 500

(Street)

BRENTWOOD

TENNESSEE

37027

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Delek US Holdings, Inc. [ DK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/17/2026		S		4,603⁽¹⁾	D	$64.383⁽²⁾	306,883	D
Common Stock	08/17/2026		S		4,623⁽¹⁾	D	$65.351⁽³⁾	302,260	D
Common Stock	08/17/2026		S		57,700⁽¹⁾	D	$66.616⁽⁴⁾	244,560	D
Common Stock	08/17/2026		S		13,074⁽¹⁾	D	$67.202⁽⁵⁾	231,486	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a 10b5-1 plan and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). These transactions complete this plan.

2. This price reflects the weighted average sale price of multiple transactions ranging from a low sale price of $63.985 per share to a high sale price of $64.950 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each sale price.

3. This price reflects the weighted average sale price of multiple transactions ranging from a low sale price of $65.010 per share to a high sale price of $65.990 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each sale price.

4. This price reflects the weighted average sale price of multiple transactions ranging from a low sale price of $66.135 per share to a high sale price of $67.130 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each sale price.

5. This price reflects the weighted average sale price of multiple transactions ranging from a low sale price of $67.135 per share to a high sale price of $67.340 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each sale price.

Remarks:

	/s/ Misty Lavender, Attorney in Fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR